Press release
Trevigen Announces a Highly Sensitive, Fluorescent, One Hour PARP Inhibition Assay
PARP Activity Diagram
Trevigen overcomes these drawbacks with the release of the HT Fluorescent Homogeneous PARP Inhibition Assay. The fluorescent assay is based on the consumption of NAD+ in the PARP ribosylation reaction where NAD+ not consumed by PARP is subsequently measured by a cycling reaction in which a highly fluorescent molecule is produced; therefore an increase in signal positively correlates to increased PARP inhibition. The subject of a Trevigen patent application, it is a simple assay requiring only 1.5 hours from start to finish. The 96 test assay requires no wash steps, and detects as little as 10% inhibition ofPARP Activity. The assay is ideal for the determination of IC50 values for PARP Inhibitors.
Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies. Visit www.trevigen.com or contact us at 1800-873-8443 or info@trevigen.com for more information.
Trevigen, Inc.
8405 Helgerman Court
Gaitherburg, MD 20877
www.trevigen.com
info@trevigen.com
1.800.873.8443
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Trevigen Announces a Highly Sensitive, Fluorescent, One Hour PARP Inhibition Assay here
News-ID: 47308 • Views: …
More Releases from Trevigen, Inc.
HT PARP in vivo Pharmacodynamic Assay II
Trevigen announces a validated assay, with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.
Pharmacodynamic (PD) assays have recently been developed and employed early in the drug screening process to assess the ability of potential drug candidates to affect molecular targets. These assays have the advantages of performing molecular proof-of-concept investigations at an early stage such as…
Trevigen Releases CultreCoat® Cell Adhesion Assays
Trevigen announces the release of seven new coated well assay kits for cell adhesion studies.
A cell’s ability to adhere to extracellular matrix (ECM) proteins is a necessary precursor to cell invasion, and this process also modulates morphogenesis, wound healing, proliferation, differentiation, and survival. Researchers studying cancer cell behavior or developing cancer therapeutics study cell adhesion with various proteins, recognizing that manipulation of cell adhesion to the extracellular environment may…
Trevigen Announces the First Standardized Comet Assay Electrophoresis System
The comet assay is the only direct method for the detection of DNA damage in cells. It is used in cancer research, in genotoxicity studies on environmental mutagens, and for screening compounds for cancer therapeutics. Based on single cell gel electrophoresis in a controlled pH environment, the assay allows the integrity of stained nuclear DNA to be examined and measured.
Until now, a lack of standardization in electrophoresis equipment, control cells,…
Trevigen announces the release of Four New Assay Kits for 3-D Cell Proliferation
Many scientists are converting from growing cells in a traditional 2-D Monolayer on plastic surfaces with tissue culture medium to “3-D” Culture. In 3-D Culture, cells are grown in a microenvironment of specialized proteins which mimics in vivo conditions and allows the cells to organize into complex structures rather than uniform monolayers. Various types of cells require different specialized proteins for optimal growth conditions and these extracellular matrices can play…
More Releases for PARP
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market 10-Year Forecast and Trends Analysis Research Report
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market Analysis, Size, Trends and Forecasts (2016-2020)
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as it is the…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
